AbbVie Inc. Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending December 30, 2020 was 22.57% (a -189.07% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth increased by 223.35%
  • Annual Research and Development (R&D) Expenses Growth for 2020 was 2.34% (a -106.16% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2019 was -37.97% (a -135.72% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2018 was 106.29% (a 649.58% increase from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending December 30, 2020 was 2.34% (a -105.16% decrease compared to previous quarter)
  • Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -106.26% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
2.34% -45.34% -34.37% -37.37%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of AbbVie Inc.

Most recent Research and Development (R&D) Expenses Growthof ABBV including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of AbbVie Inc.

AbbVie Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 22.57% -25.34% 22.54% 6.98% 2.34%
2019 -76.26% 80.21% -2.34% 3.62% -37.97%
2018 361.29% 3.26% 7.57% 8.93% 106.29%
2017 16.46% 11.03% 9.34% 20.72% 14.18%
2016 12.47% -22.0% 14.58% 16.65% 2.33%
2015 22.3% 74.63% 17.63% 5.05% 29.97%
2014 10.15% 13.73% 17.63% 21.77% 15.48%
2013 17.18% -12.18% 10.44% -1.25% 2.77%
2012 -73.84% 0.0% 0.0% 9.35% 6.11%
2011 4.93%
2010 46.13%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.